Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis

Abstract

BackgroundMultiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) for which several new treatment options were recently introduced. Among them is the monoclonal anti-CD52 antibody alemtuzumab that depletes mainly B cells and T cells in the immune periphery. Considering the ongoing controversy about the involvement of B cells and in particular the formation of B cell aggregates in the brains of progressive MS patients, an in-depth understanding of the effects of anti-CD52 antibody treatment on the B cell compartment in the CNS itself is desirable.MethodsWe used myelin basic protein (MBP)-proteolipid protein (PLP)-induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 (B6) mice as B cell-dependent model of MS. Mice were treated intraperitoneally either at the peak of EAE or at 60 days after onset with 200 μg murine anti-CD52 vs. IgG2a isotype control antibody for five consecutive days. Disease was subsequently monitored for 10 days. The antigen-specific B cell/antibody response was measured by ELISPOT and ELISA. Effects on CNS infiltration and B cell aggregation were determined by immunohistochemistry. Neurodegeneration was evaluated by Luxol Fast Blue, SMI-32, and Olig2/APC staining as well as by electron microscopy and phosphorylated heavy neurofilament serum ELISA.ResultsTreatment with anti-CD52 antibody attenuated EAE only when administered at the peak of disease. While there was no effect on the production of MP4-specific IgG, the treatment almost completely depleted CNS infiltrates and B cell aggregates even when given as late as 60 days after onset. On the ultrastructural level, we observed significantly less axonal damage in the spinal cord and cerebellum in chronic EAE after anti-CD52 treatment.ConclusionAnti-CD52 treatment abrogated B cell infiltration and disrupted existing B cell aggregates in the CNS.Electronic supplementary materialThe online version of this article (10.1186/s12974-018-1263-9) contains supplementary material, which is available to authorized users.

A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo

“…B220 (CD45R) and PDCA-1 (BST2) are important specific phenotype markers of pDCs (Narendra et al, 2014;Kostarnoy et al, 2017). However, B220 was expressed not only on pDCs, but also on B cells and activated T cells (Simon et al, 2018). Therefore, PDCA-1 was considered the more accurate and specific marker.…”

Targeting Acute Islet Inflammation to Preserve Graft Mass and Long-Term Function

“…Multiple mechanisms have been proposed for actions of alemtuzumab including antibody-dependent cellmediated (ADCC) and complement-dependent (CDC) cytotoxicity toward T cells and B cells with high expression of glycosylphosphatidylinositol-linked surface protein CD52. It has sparing effects toward immature lymphocytes and innate immune cells having relatively low CD52 expression and preserves regulatory T cells that may contribute to graft survival [14,16,17]. Indeed, alemtuzumab treatment in a humanized mouse model showed that natural killer cells and neutrophils contribute to lymphocyte depletion independently of CDC.…”

Shikonin ameliorates Experimental Autoimmune Encephalomyelitis (EAE) via Immuno-modulatory, anti-apototic, and anti-oxidative activity

“…Multiple Sclerosis (MS) is a common auto-immuno-in ammatory and neurodegenerative disease in youth, affecting CNS (1). A combination of genetic, environmental and infectious factors are involved in the disease development (2). MS is described by central demyelinating in the white matter of the CNS and eventually lead to oligodendrocytes apoptosis (3).…”